|
Fri, 12/07/2018 - 15:57 |
WATCH: A code for reprogramming immune sentinels |
LundUniv |
|
Thu, 12/06/2018 - 21:29 |
Update on the Phase III EAGLE trial of Imfinzi and tremelimumab in advanced head and neck cancer |
AstraZeneca |
|
Thu, 12/06/2018 - 10:48 |
Most promising European start-ups awarded at EIT Health Summit |
EIT |
|
Mon, 11/26/2018 - 08:28 |
EIT Health: European Health Catapult finalists announced |
EIT |
|
Fri, 11/16/2018 - 05:55 |
AstraZeneca provides update on the Phase III MYSTIC trial of Imfinzi and tremelimumab in Stage IV non-small cell lung cancer |
AstraZeneca |
|
Tue, 10/23/2018 - 03:22 |
AstraZeneca strengthens and expands oncology development and commercialisation collaboration with Innate Pharma |
AstraZeneca |
|
Sat, 10/20/2018 - 23:05 |
Roches investigational personalised medicine entrectinib shrank tumours in people with NTRK fusion-positive solid tumours |
Rocheusa |
|
Wed, 10/17/2018 - 05:43 |
Roche reports very strong growth in the first nine months of 2018 |
Rocheusa |
|
Tue, 10/16/2018 - 21:20 |
Unexpected role of enzyme may help develop anti-cancer drugs |
UniversityColle... |
|
Mon, 10/15/2018 - 04:57 |
Roche launches NGS AVENIO Tumor Tissue Analysis Kits for oncology research |
Rocheusa |
|
Mon, 09/24/2018 - 22:10 |
Imfinzi is the first immunotherapy to demonstrate significant overall survival benefit in unresectable, Stage III lung cancer |
AstraZeneca |
|
Mon, 09/24/2018 - 18:51 |
Roche announces global availability of blood-based genomic profiling test, FoundationOne Liquid |
Rocheusa |
|
Mon, 09/24/2018 - 18:01 |
Roches investigational medicine entrectinib showed a durable response of more than two years in people with a specific type of lung cancer |
Rocheusa |
|
Sun, 09/23/2018 - 20:29 |
European Commission approves Imfinzi for locally-advanced, unresectable NSCLC |
AstraZeneca |
|
Fri, 07/27/2018 - 09:31 |
Imfinzi receives positive EU CHMP opinion for locally-advanced, unresectable non-small cell lung cancer |
AstraZeneca |
|
Tue, 07/24/2018 - 09:34 |
GSK and Adaptimmune complete transition of NY-ESO SPEAR T-cell therapy programme to GSK |
GlaxoSmithKline |
|
Thu, 07/05/2018 - 09:43 |
265 million investment in UCL spin-outs which could transform patient outcomes |
UniversityColle... |
|
Sun, 07/01/2018 - 21:49 |
Imfinzi approved in Japan for unresectable Stage III non-small cell lung cancer |
AstraZeneca |
|
Fri, 05/25/2018 - 02:08 |
Imfinzi significantly improves overall survival in the Phase III PACIFIC trial for unresectable Stage III non-small cell lung cancer |
AstraZeneca |
|
Wed, 04/25/2018 - 21:03 |
Roche reports a strong start in 2018 |
Rocheusa |
|
Mon, 04/23/2018 - 23:36 |
AstraZeneca reports results from the ARCTIC trial in third-line non-small cell lung cancer |
AstraZeneca |
|
Sat, 03/10/2018 - 22:57 |
AstraZeneca provides update on MYSTIC trial timeline |
AstraZeneca |
|
Thu, 03/01/2018 - 12:27 |
Aggressive brain tumours carry potential target for engineered immune cells |
Cancer Research UK |
|
Fri, 02/02/2018 - 09:39 |
MP Thangam Debbonaire visits Bristol to meet scientists behind cutting edge cancer research |
University of B... |
|
Thu, 12/21/2017 - 23:53 |
Roche and Ignyta reach definitive merger agreement |
Rocheusa |
